title: Conjugated linoleic acid supplementation reduces peripheral blood mononuclear cell interleukin-2 production in healthy middle-aged males.
abstract: Conjugated linoleic acid (CLA) refers to geometric and positional isomers of linoleic acid. Animal studies have shown that CLA modulates the immune system and suggest that it may have a therapeutic role in inflammatory disorders. This double-blind placebo-controlled intervention trial investigated the effects of CLA supplementation on indices of immunity relating to cardiovascular disease (CVD) in a cohort of healthy middle-aged male volunteers. Subjects were randomly assigned to supplement their diet with 2.2 g 50:50 isomeric blend of cis 9, trans 11 (c9, t11)-CLA and trans 10, cis 12 (t10, c12)-CLA or placebo daily for 8 weeks. Interleukin (IL) 2, IL-10 and tumour necrosis factor (TNF) alpha were measured in the supernatant of cultured unstimulated and concanavalin A (Con A)-stimulated peripheral blood mononuclear cells (PBMC) by ELISA. Serum IL-6 and plasma CRP were measured by ELISA and plasma fibrinogen by automated clotting assay. Gene expression was investigated by real-time RT-PCR. CLA supplementation significantly reduced Con A-stimulated PBMC IL-2 secretion (37.1%; P=.02). CLA supplementation had no significant effect on transcription of IL-2. CLA supplementation had no direct significant effects on PBMC TNFalpha or IL-10 secretion. Other inflammatory markers associated with CVD, including IL-6, CRP and fibrinogen, were not affected by CLA supplementation. This study showed that CLA supplementation reduced PBMC IL-2 secretion from Con A-stimulated PBMC but lacked effect on other markers of the human inflammatory response.
authors: Nutrigenomics Research Group, Department of Clinical Medicine and Institute of Molecular Medicine, St. James's Hospital, Dublin 8, Ireland.
authors: Anne
authors: A
authors: Mullen
authors: Fiona
authors: F
authors: Moloney
authors: Anne P
authors: AP
authors: Nugent
authors: Lorna
authors: L
authors: Doyle
authors: Kevin D
authors: KD
authors: Cashman
authors: Helen M
authors: HM
authors: Roche
mesh_terms: D000328:Adult; D003208:Concanavalin A / Q000494:pharmacology; D004311:Double-Blind Method; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D044243:Linoleic Acids, Conjugated / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: C094849:10,12-octadecadienoic acid; C508609:IL10 protein, human; C508594:IL2 protein, human; D007376:Interleukin-2; D044243:Linoleic Acids, Conjugated; D014409:Tumor Necrosis Factor-alpha; D003208:Concanavalin A; D016753:Interleukin-10; C046938:9,11-linoleic acid